

# iGUIDE Summary Report

*report generated : 2018-11-16*

*software version : v0.2.4*

*environment build : v0.1.0*

## Contents

|  |          |
|--|----------|
| <b>Summary</b>   | <b>2</b> |
| <b>Specimen overview</b>                                   | <b>3</b> |
| <b>On-target analysis</b>                                  | <b>4</b> |
| Specimen breakdown . . . . .                               | 5        |
| Editing near known genomic sites . . . . .                 | 5        |
| <b>Off-target analysis</b>                                 | <b>7</b> |
| Specimen breakdown . . . . .                               | 7        |
| Off-target enrichment in cancer-associated genes . . . . . | 8        |
| Genomic distribution of incorporation sites . . . . .      | 9        |
| Off-target gRNA sequence comparison . . . . .              | 11       |

---

This report includes data from the following sequencing runs: iGUIDE Set1, iGUIDE Set2, iGUIDE Set3, and iGUIDE Set8.

# Summary

The following document summarizes the results of processing iGUIDE Set1, iGUIDE Set2, iGUIDE Set3, and iGUIDE Set8 sequencing set(s) through the iGUIDE pipeline. Included in this document are explanations of the data analytics as well as tables and graphics of the data obtained from the sequence analysis. This report includes 16 specimens treated with 4 guide RNAs. A total of 18,626,117 reads are considered in this analysis, which represent 476,405 inferred cells sampled.

# Specimen overview

Table 1: Specimen summary.

| specimen | RNP  | gRNA    | dsODN | Reads     | UMItags | Alignments |
|----------|------|---------|-------|-----------|---------|------------|
| iG06     | Cas9 | B2M     | iG    | 1,589,790 | 160,103 | 28,538     |
| iG07     | Cas9 | B2M     | iG    | 1,208,094 | 90,823  | 17,870     |
| iG08     | Cas9 | B2M     | iG    | 1,666,816 | 103,375 | 23,750     |
| iG09     | Cas9 | B2M     | iG    | 1,342,608 | 92,095  | 18,776     |
| iG10     | Cas9 | B2M     | iG    | 1,142,739 | 60,698  | 15,365     |
| iG16     | Cas9 | TRAC5   | iG    | 1,469,857 | 96,048  | 21,997     |
| iG17     | Cas9 | TRAC5   | iG    | 563,759   | 44,027  | 12,780     |
| iG18     | Cas9 | TRAC5   | iG    | 894,124   | 87,299  | 18,762     |
| iG19     | Cas9 | TRAC5   | iG    | 1,202,450 | 77,287  | 23,240     |
| iG20     | Cas9 | TRAC5   | iG    | 1,128,364 | 107,017 | 21,344     |
| iG48     | Cas9 | VEGFAs2 | iG    | 985,533   | 96,680  | 48,290     |
| iG49     | Cas9 | VEGFAs2 | iG    | 1,337,602 | 145,269 | 59,910     |
| iG50     | Cas9 | VEGFAs2 | iG    | 1,877,187 | 199,180 | 82,053     |
| iG54     | Cas9 | VEGFAs3 | iG    | 685,907   | 59,987  | 26,506     |
| iG55     | Cas9 | VEGFAs3 | iG    | 1,068,461 | 109,833 | 37,754     |
| iG56     | Cas9 | VEGFAs3 | iG    | 462,826   | 44,266  | 19,470     |

Each specimen started in the iGUIDE pipeline as genomic DNA. The gDNA was randomly sheared through ultrasonication and ligated with barcoded DNA linkers. Nested-PCR was used to amplify from incorporated dsODN sequences to the linker sequences with barcoded and linker-specific primers. This dual barcoding reduces sample to sample crossover. Amplicons were sequenced on an Illumina platform and the sequencing data processed with the iGUIDE software, available on [GitHub@cnobles/iGUIDE](https://github.com/cnobles/iGUIDE).

DNA sequence reads were aligned to the hg38 reference genome. The number of reads aligning for each specimen is displayed in **Table 1**, along with the number of unique alignments they represent (the inferred cells sampled). Multiple reads may represent a singular alignment of genomic DNA, inherent to sequence analysis of amplified DNA. These alignments indicate individual events of dsODN incorporation and clonal expansion.

Alternatively, random nucleotide sequences are included in the ligated linker sequences. These Unique Molecular Indexes (UMItags) can provide another method of abundance by counting the number of UMItags and breakpoint position combinations for each incorporation sites. This method of quantification has an increased dynamic range, yet can suffer from PCR artifacts leading to inflated abundances.

## On-target analysis

Incorporation sites, or locations in the genome where the dsODN was detected, are expected to be in the proximity of RNA-guided nuclease targeted locations. The guide RNAs provided for these analyses and their On-target locations (loci) are shown in **Table 2**. The genomic locations are in a format where chromosome, orientation, and nucleotide position are delimited by a colon (“:”).

Table 2: Guide RNAs and associated information.

| Guide   | gRNA                 | PAM | Edit Locus       |
|---------|----------------------|-----|------------------|
| B2M     | GAGTAGCGCGAGCACAGCTA | NGG | chr15:-:44711569 |
| TRAC5   | TGTGCTAGACATGAGGTCTA | NGG | chr14:+:22547664 |
| VEGFAs2 | GACCCCTCCACCCCGCCTC  | NGG | chr6:-:43770825  |
| VEGFAs3 | GGTGAGTGAGTGTGTGCGTG | NGG | chr6:+:43769733  |

Analysis of On-target associated incorporation sites (**Table 3**) produces several features that are helpful in On- and Off-target site characterization. These include the following:

- Alignment **Pileups**: unique alignments that overlap with each other or “pileup”, suggesting a nearby location may be targeted for a double strand break (DSB). For this analyses, any group of 3 or more unique alignments were considered as a pileup cluster.
- Flanking **Paired** alignments: alignments can be found on either side of a DSB, and therefore identifying flanking alignments suggests a DSB could be found between the paired alignments. Flanking alignments were searched for in these data up to 200 bp from each other.
- gRNA **Matched** alignments: searching for the guide RNA sequence upstream of the incorporation site can be an indicator of guided nuclease activity. While this indicator may seem to be crucial, guide RNAs have been demonstrated to have a variety of behaviors when annealing to target DNA, not all of which can be easily searched for with a simple sequence alignment. Nucleotide sequence matching treated gRNA sequences were searched for up to 100 bp upstream of the incorporation sites and required to have no more than 6 mismatches.

Specimen specific tables with data relating to these criteria are found in **Table 3** for percent On-target editing and **Table 4** for identified Off-target loci.

## Specimen breakdown

**Table 3** displays the percent of cells sampled that were associated with On-target loci for **All** alignments. Further the percentages for **Pileups**, **Paired**, and **Matched** criteria are displayed in the following columns.

Table 3: Percent On-target.

| Specimen | Treatment | Condition           | All Align. | Align. Pileups | Flanking Pairs | gRNA Matched |
|----------|-----------|---------------------|------------|----------------|----------------|--------------|
| iG06     | B2M       | Cas9 - B2M - iG     | 6.994      | 70.55          | 96.88          | 99.75        |
| iG07     | B2M       | Cas9 - B2M - iG     | 7.224      | 69.86          | 98.09          | 99.77        |
| iG08     | B2M       | Cas9 - B2M - iG     | 5.916      | 59.43          | 96.79          | 99.72        |
| iG09     | B2M       | Cas9 - B2M - iG     | 7.936      | 73.22          | 97.88          | 99.87        |
| iG10     | B2M       | Cas9 - B2M - iG     | 8.721      | 72.2           | 98.52          | 100          |
| iG16     | TRAC5     | Cas9 - TRAC5 - iG   | 3.164      | 48.88          | 91.13          | 99.14        |
| iG17     | TRAC5     | Cas9 - TRAC5 - iG   | 4.21       | 65.05          | 98.53          | 99.26        |
| iG18     | TRAC5     | Cas9 - TRAC5 - iG   | 4.061      | 63.18          | 97.3           | 98.7         |
| iG19     | TRAC5     | Cas9 - TRAC5 - iG   | 2.22       | 47.91          | 94.46          | 99.23        |
| iG20     | TRAC5     | Cas9 - TRAC5 - iG   | 2.928      | 54.68          | 95.55          | 98.27        |
| iG48     | VEGFAs2   | Cas9 - VEGFAs2 - iG | 1.145      | 2.105          | 2.538          | 2.274        |
| iG49     | VEGFAs2   | Cas9 - VEGFAs2 - iG | 1.168      | 2.537          | 2.705          | 2.75         |
| iG50     | VEGFAs2   | Cas9 - VEGFAs2 - iG | 1.066      | 2.481          | 2.675          | 2.717        |
| iG54     | VEGFAs3   | Cas9 - VEGFAs3 - iG | 16.93      | 25.94          | 54.76          | 27.16        |
| iG55     | VEGFAs3   | Cas9 - VEGFAs3 - iG | 14.29      | 25.64          | 54.79          | 27.33        |
| iG56     | VEGFAs3   | Cas9 - VEGFAs3 - iG | 17.37      | 26.6           | 55.27          | 27.35        |

## Editing near known genomic sites

**Figure 1** displays the distribution of dsODN incorporations around on-target site(s). Incorporations in different orientations are shown on the positive (red) and negative (blue) y-axis. The percentage in the bottom right corner of each plot is an estimate of the number of incorporations associated with the on-target site (based on pileups) captured within the allowed window of 100 bps. These data can be used to fine tune the processing analyses, specifically the `upstreamDist` parameter which modifies the distance upstream of incorporation sites to search for nuclease edited sequences.




Figure 1: Distance distribution of observed incorporation sites from On-target loci.

# Off-target analysis

## Specimen breakdown

Using the criteria discussed previously based on characterizing features of nuclease targeted sites, off-target sites can be selected from the data in an unbiased manner. **Table 4** shows a summary of the unique off-target locations (loci) observed in the data. For **All** alignments, the loci are based on overlapping alignments (pileup cluster), without a minimum number of fragments required to be classified as a pileup cluster. **Pileup** loci are similarly based on overlapping alignments, but require at least 3 alignments to form a cluster. Flanking **Paired** loci require at least two unique alignments with opposite orientation (strands). Guide RNA **Matched** loci require a match in the upstream sequence to a treated gRNA (within 6 mismatches out of the 20 nts and zero PAM mismatches).

Table 4: Off-target Loci.

| Specimen | Treatment | Condition           | All Align. | Align. Pileups | Flanking Pairs | gRNA Matched |
|----------|-----------|---------------------|------------|----------------|----------------|--------------|
| iG06     | B2M       | Cas9 - B2M - iG     | 24,636     | 223            | 27             | 4            |
| iG07     | B2M       | Cas9 - B2M - iG     | 15,315     | 140            | 10             | 3            |
| iG08     | B2M       | Cas9 - B2M - iG     | 20,391     | 234            | 20             | 4            |
| iG09     | B2M       | Cas9 - B2M - iG     | 16,037     | 140            | 14             | 2            |
| iG10     | B2M       | Cas9 - B2M - iG     | 12,957     | 128            | 9              | 0            |
| iG16     | TRAC5     | Cas9 - TRAC5 - iG   | 19,687     | 188            | 30             | 6            |
| iG17     | TRAC5     | Cas9 - TRAC5 - iG   | 11,554     | 75             | 4              | 4            |
| iG18     | TRAC5     | Cas9 - TRAC5 - iG   | 16,908     | 119            | 10             | 8            |
| iG19     | TRAC5     | Cas9 - TRAC5 - iG   | 21,438     | 138            | 14             | 4            |
| iG20     | TRAC5     | Cas9 - TRAC5 - iG   | 19,491     | 130            | 12             | 10           |
| iG48     | VEGFAs2   | Cas9 - VEGFAs2 - iG | 21,898     | 628            | 262            | 379          |
| iG49     | VEGFAs2   | Cas9 - VEGFAs2 - iG | 31,918     | 676            | 283            | 381          |
| iG50     | VEGFAs2   | Cas9 - VEGFAs2 - iG | 45,998     | 795            | 377            | 430          |
| iG54     | VEGFAs3   | Cas9 - VEGFAs3 - iG | 9,045      | 255            | 55             | 136          |
| iG55     | VEGFAs3   | Cas9 - VEGFAs3 - iG | 16,389     | 378            | 74             | 181          |
| iG56     | VEGFAs3   | Cas9 - VEGFAs3 - iG | 6,620      | 169            | 42             | 122          |

## Off-target enrichment in cancer-associated genes

Flanking **Paired** loci and gRNA **Matched** loci are tested for enrichment against specific gene lists in **Table 5**. The cancer-associated and special gene lists (adjusted in the config file) included in this analysis were: [http://bushmanlab.org/assets/doc/allOnco\\_Feb2017.tsv](http://bushmanlab.org/assets/doc/allOnco_Feb2017.tsv) and <http://bushmanlab.org/assets/doc/humanLymph.tsv>. Enrichment was tested by Fisher’s Exact and p-values were adjusted for multiple comparisons using a Benjamani-Hochberg correction. Omitted specimens or conditions had insufficient data for this analysis (Total Gene Count = 0).

Table 5: Cancer-associated Gene editing enrichment.

| Origin         | Condition           | Total Gene Count | Onco Related Count | Special Gene Count | Onco Enrich. p-value | Special Enrich. p-value |
|----------------|---------------------|------------------|--------------------|--------------------|----------------------|-------------------------|
| Reference      | Random              | 2949             | 265                | 5                  | 1.000                | 1.000                   |
| Flanking Pairs | Cas9 - B2M - iG     | 85               | 12                 | 0                  | 0.184                | 1.000                   |
| Flanking Pairs | Cas9 - TRAC5 - iG   | 75               | 10                 | 0                  | 0.280                | 1.000                   |
| Flanking Pairs | Cas9 - VEGFAs2 - iG | 925              | 157                | 3                  | <b>0.000</b>         | 0.731                   |
| Flanking Pairs | Cas9 - VEGFAs3 - iG | 174              | 31                 | 5                  | <b>0.001</b>         | <b>0.000</b>            |
| gRNA Matched   | Cas9 - B2M - iG     | 18               | 8                  | 0                  | <b>0.000</b>         | 1.000                   |
| gRNA Matched   | Cas9 - TRAC5 - iG   | 37               | 5                  | 1                  | 0.425                | 0.216                   |
| gRNA Matched   | Cas9 - VEGFAs2 - iG | 1193             | 214                | 4                  | <b>0.000</b>         | 0.653                   |
| gRNA Matched   | Cas9 - VEGFAs3 - iG | 442              | 122                | 30                 | <b>0.000</b>         | <b>0.000</b>            |



## Genomic distribution of incorporation sites

The figure(s) below display the genomic distribution of identified incorporation sites. The inner most ring plots all alignments identified within the associated data, while subsequent rings plot the alignments associated with Pileups, Flanking Pairs, and gRNA Matched groups. The height of the bar within its associated ring is correlated to the number of incorporations identified within the **10 Mb window** (normalized logarithm base 10 of incorporation sites).

**Levels** ■ All Align. ■ Pileup Align. ■ Flanking Pairs ■ gRNA Matched




Figure 2: Genomic distribution of incorporation sites by bioinformatic characteristics.

## Off-target gRNA sequence comparison

Off-target sites are identified by sequence similarity within 100 bp upstream of incorporation sites. The sequences of the gRNA matched sites are displayed below in Figure 3 along with the number of mismatches to the gRNA sequence (**mismatch**), an indication if the site is associated with an on- or off-target location (**target**), the total number of unique alignments associated with the site (**aligns**), the maximum edit site likelihood (**MESL**), and an identifier denoted by the nearest gene (**gene\_id**). MESL is a score for the percentage likelihood the off-target site is associated with directed nuclease editing, based solely on the respective On-target incorporation distribution. The gene name within the **gene\_id** is the nearest gene to the genomic location. Further, symbols after the gene name indicate \*) that the site is within the transcription unit of the gene, ~) the gene appears on the cancer-association list, !) and that the gene appears on the special gene list. For this report, gene lists used were: [http://bushmanlab.org/assets/doc/allOnco\\_Feb2017.tsv](http://bushmanlab.org/assets/doc/allOnco_Feb2017.tsv) and <http://bushmanlab.org/assets/doc/humanLymph.tsv>.

**Cas9 - B2M - iG**  
gRNA: B2M

| Sequence                | mismatch | target | aligns | MESL | gene_id    |
|-------------------------|----------|--------|--------|------|------------|
| GAGTAGCGCGAGCACAGCTANGG |          |        |        |      |            |
| .....A..                | 0        | On     | 7,522  | 95.8 | B2M*~      |
| ..GAT..G..GG..G..       | 6        | Off    | 2      | 21.8 | CCDC182    |
| ATC..AG..T..G..G..      | 6        | Off    | 1      | 81.9 | GMFG       |
| TG..AG..G..C..T..       | 6        | Off    | 1      | 25.0 | MCF2L*     |
| AG..AG..T..A..T..       | 6        | Off    | 1      | 21.7 | PIEZO2*    |
| ..G..G..G..C..T..GT..   | 6        | Off    | 1      | 21.6 | RARG~      |
| ..A..T..TG..GA..A..     | 6        | Off    | 1      | 21.4 | STEAP2-AS1 |
| ..C..A..G..GT..GT..     | 6        | Off    | 1      | 21.4 | MUC5AC*~   |
| C..C..T..A..A..A..G..   | 6        | Off    | 1      | 21.3 | MTX2       |
| ..T..A..G..T..A..T..    | 6        | Off    | 1      | 20.6 | LINC00856  |

**Cas9 - TRAC5 - iG**  
gRNA: TRAC5

| Sequence                     | mismatch | target | aligns | MESL | gene_id   |
|------------------------------|----------|--------|--------|------|-----------|
| TGTGCTAGACATGAGGTCTANGG      |          |        |        |      |           |
| .....T..                     | 0        | On     | 3,135  | 95.7 | DAD1      |
| ..C..G..T..C..C..A..         | 6        | Off    | 2      | 31.5 | CMIP*     |
| T..C..A..C..A..C..G..        | 6        | Off    | 2      | 26.7 | AFF3~     |
| AA..TG..A..A..A..A..         | 5        | Off    | 2      | 24.7 | FAM19A2   |
| A..C..TT..A..A..G..A..A..C.. | 4        | Off    | 1      | 95.7 | JAKMIP1*~ |
| ..A..A..A..A..A..A..C..      | 6        | Off    | 1      | 58.7 | ADARB2~   |
| CA..A..A..T..G..C..T..       | 6        | Off    | 1      | 40.8 | LINC01173 |
| G..T..G..C..A..A..A..        | 5        | Off    | 1      | 36.0 | LINC01179 |
| T..T..T..TTT..C..A..         | 6        | Off    | 1      | 34.8 | C3orf58   |
| ..AA..T..A..A..G..           | 4        | Off    | 1      | 32.9 | KIAA1210* |

**Cas9 - VEGFAs2 - iG**  
gRNA: VEGFAs2

| Sequence               | mismatch | target | aligns | MESL | gene_id   |
|------------------------|----------|--------|--------|------|-----------|
| GACCCCTCCACCCCGCCTCNGG |          |        |        |      |           |
| ATT..C..A..A..         | 4        | Off    | 10,281 | 95.3 | HDLBP*~   |
| CT..AC..A..A..         | 4        | Off    | 5,533  | 95.3 | LINC01258 |
| CTA..A..C..C..         | 3        | Off    | 4,827  | 95.3 | PAPD7*    |
| TG..TC..T..T..         | 4        | Off    | 4,484  | 95.3 | ACLY*     |
| C..AC..T..T..          | 3        | Off    | 4,465  | 95.3 | LAMA3*    |
| CC..C..C..A..A..       | 4        | Off    | 4,163  | 95.3 | CLYBL*    |
| CC..C..C..C..C..       | 4        | Off    | 2,883  | 95.3 | SBF1*     |
| TG..C..A..T..T..       | 4        | Off    | 2,654  | 95.3 | HERPUD1~  |
| ACA..C..A..A..A..      | 4        | Off    | 2,532  | 95.3 | PLPPR1    |
| .GG..T..T..T..         | 2        | Off    | 2,328  | 95.3 | PAX6*~    |

**Cas9 - VEGFAs3 - iG**  
gRNA: VEGFAs3

| Sequence                    | mismatch | target | aligns | MESL | gene_id   |
|-----------------------------|----------|--------|--------|------|-----------|
| GGTGTAGTGTGAGTGTGTGCGTGNNGG |          |        |        |      |           |
| .....T..                    | 0        | On     | 13,261 | 96.5 | VEGFA~    |
| A..T..C..G..GT..A..         | 6        | Off    | 13,261 | 96.5 | VEGFA~    |
| A..G..T..T..G..G..          | 2        | Off    | 5,283  | 96.5 | MAX*~     |
| T..G..A..A..A..             | 2        | Off    | 4,480  | 96.5 | COMMD10*  |
| C..A..A..T..T..T..          | 2        | Off    | 3,597  | 96.5 | CYTH4     |
| AC..T..A..A..A..            | 3        | Off    | 844    | 96.5 | ZNF780B*  |
| A..A..A..A..A..             | 3        | Off    | 508    | 96.5 | LINC01339 |
| A..T..T..T..T..T..          | 2        | Off    | 481    | 96.5 | CFAP61*   |
| T..T..A..T..C..T..G..       | 6        | Off    | 481    | 96.5 | CFAP61*   |
| A..T..C..G..G..A..G..       | 6        | Off    | 481    | 85.8 | CFAP61*   |

Figure 3: Sequence similarity between off-target sites and targeting gRNA(s).